The Latest Cardiac and Vascular News
Global collaborative aims to improve cardiovascular health NEW YORK–(BUSINESS WIRE)–Accenture (NYSE: ACN) has joined AI4BetterHearts, a global data collaborative founded by Microsoft and the Novartis Foundation, that aims to help stakeholders— from policy makers to patients— make better decisions about heart health and improve the health of entire populations. Cardiovascular […]
This innovative study is the first to characterize the metabolites of TOTUM•070 in humans and their mode of action in the liver in a population of 10 healthy volunteers. TOTUM•070 was tested at its clinical daily dose (5g), used also in the Phase II HEART clinical trial. Metabolomic analysis confirms […]
Data from RADIANCE-II will build on evidence from RADIANCE-HTN SOLO and TRIO studies to support pre-market application to the FDA PALO ALTO, Calif.–(BUSINESS WIRE)–ReCor Medical, Inc. (“ReCor”), a fully owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today completion of enrollment in their RADIANCE-II pivotal trial of the Paradise […]
Marks First Health Technology Assessment (HTA) Reimbursement in Europe and Initiation of Next Phase of the Company’s Growth Strategy Company Provides Progress Update on European and International Expansion Plans DUBLIN, Ireland and BRIDGEWATER, N.J., March 28, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announces that the Company received […]
The studies will assess the performance of its HLT Meridian® TAVR® Valve System to treat aortic stenosis and aortic regurgitation for high-risk patients suffering from aortic disease MAPLE GROVE, Minn., March 24, 2022 /PRNewswire/ — HLT Inc., a Bracco Group Company and a leader in the development of cutting edge transcatheter aortic valve replacement (TAVR) therapy, […]
This New Milestone Follows the Company’s Successful Exploration of the HeartPoint Global Implant System in the Arterial Branches Ready for Clinical Trials to Start TEL AVIV, Israel, March 22, 2022 /PRNewswire/ — HeartPoint Global, a leading medical device company dedicated to providing high-quality, minimally invasive cardiac care globally, announced another major milestone in […]
Impulse Dynamics Is Now Among the First US-based Manufacturers of Active Implantable Devices To Receive Certification MARLTON, N.J., March 22, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a company dedicated to innovative treatments for chronic heart failure, is pleased to announce that it has successfully completed the requirements for certification of […]
Coalition aims to raise awareness and utilization of cardiogenomic testing to improve patient outcomes. WASHINGTON, March 22, 2022 /PRNewswire/ — Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic […]
New Procedure Reimbursement Code Expected to Enhance Study Performance for Clinical Centers Participating in the CardiAMP Cell Therapy Heart Failure Trial and the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial SUNNYVALE, Calif., March 22, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment […]
LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, eligible for PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is strengthening its commitment to Corporate Social Responsibility (CSR) by joining the United Nations Global Compact and applying […]
